Vanda Pharmaceuticals (VNDA) EBT (2010 - 2026)

Vanda Pharmaceuticals has disclosed EBT across 17 years of filings, most recently posting -$48.4 million for Q1 2026.

• EBT for Q1 2026 came in at -$48.4 million, down 29.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$149.7 million (down 169.13% YoY), and the FY2025 annual result was -$138.6 million, down 504.89% from the prior year.
• EBT came in at -$48.4 million for Q1 2026 at Vanda Pharmaceuticals, down from -$38.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $9.6 million in Q4 2022 to a low of -$48.4 million in Q1 2026.
• The 5-year median for EBT is -$5.5 million (2024), against an average of -$11.3 million.
• Across the five-year window, EBT soared 173.08% in 2023 and tumbled 5103.33% in 2024, its largest moves.
• Vanda Pharmaceuticals' EBT stood at $9.6 million in 2022, then plunged by 117.28% to -$1.7 million in 2023, then tumbled by 291.15% to -$6.5 million in 2024, then tumbled by 484.92% to -$38.0 million in 2025, then dropped by 27.42% to -$48.4 million in 2026.
• The last three EBT figures came in at -$48.4 million (Q1 2026), -$38.0 million (Q4 2025), and -$28.4 million (Q3 2025), per Business Quant data.